NCT04664361

Effect of NMN on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity

Completed NA Last updated 17 January 2024

What this trial tests

NA trial testing Nicotinamide mononucleotide in Physical Activity in 131 participants. Completed in 30 May 2023.

Timeline

9 March 2021

Primary endpoint
10 November 2022

30 May 2023

Quick facts

Lead sponsor	Seneque SA
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	supportive care
Enrollment	131
Start date	9 March 2021
Primary completion	10 November 2022
Estimated completion	30 May 2023
Sites	1 location across France

Drugs / interventions tested

• Nicotinamide mononucleotide — full drug profile →
• Placebo

Conditions studied

• Physical Activity — all drugs for Physical Activity →
• Muscle Recovery — all drugs for Muscle Recovery →

Sponsor

Seneque SA

Who can join

Adults 20 to 49, male only, with Physical Activity or Muscle Recovery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the effect of NMN supplementation (250 and 500 mg/day over 38 days) compared to placebo in healthy volunteers with moderate physical activity on muscle recovery, physical capacity, cardiorespiratory recovery, the perception of the arduousness of the effort, the variation in blood lactate levels before and after physical exercise, the perception of the intensity of post-exercise muscle pain (cramps), the body composition and Nicotinamide-Adenine Mononucleotide (NAD+) level in blood.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. Epigenetic regulation of aging: implications for interventions of aging and diseases.
   Wang K, Liu H, Hu Q, Wang L, et al · · 2022 · cited 406× · PMID 36336680 · DOI 10.1038/s41392-022-01211-8
2. NAD⁺ in COVID-19 and viral infections.
   Zheng M, Schultz MB, Sinclair DA. · · 2022 · cited 46× · PMID 35221228 · DOI 10.1016/j.it.2022.02.001
3. NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health.
   Alegre GFS, Pastore GM. · · 2023 · cited 44× · PMID 37273100 · DOI 10.1007/s13668-023-00475-y
4. A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults.
   Huang H. · · 2022 · cited 38× · PMID 35821806 · DOI 10.3389/fragi.2022.851698
5. Potential Synergistic Supplementation of NAD+ Promoting Compounds as a Strategy for Increasing Healthspan.
   Sharma A, Chabloz S, Lapides RA, Roider E, et al · · 2023 · cited 35× · PMID 36678315 · DOI 10.3390/nu15020445
6. Therapeutic Effects of Anti-Inflammatory and Anti-Oxidant Nutritional Supplementation in Retinal Ischemic Diseases.
   Lee D, Fu Z, Hellstrom A, Smith LEH. · · 2024 · cited 5× · PMID 38791541 · DOI 10.3390/ijms25105503
7. Toxicology study profile of Nicotinamide mononucleotide after acute and 90-day sub chronic dosing in Wistar rats and mutagenicity tests.
   Yu J, Shen Q, Li J. · · 2024 · cited 1× · PMID 38765763 · DOI 10.1016/j.crtox.2024.100171